key: cord-0266121-0tk5u50w
authors: Isaikina, Polina; Tsai, Ching-Ju; Dietz, Nikolaus; Pamula, Filip; Grahl, Anne; Goldie, Kenneth N.; Guixà-González, Ramon; Schertler, Gebhard F.X.; Hartley, Oliver; Stahlberg, Henning; Maier, Timm; Deupi, Xavier; Grzesiek, Stephan
title: Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist
date: 2020-11-27
journal: bioRxiv
DOI: 10.1101/2020.11.27.401117
sha: 4d71d3af9df364fb430ff69571ee354c3be7a3f6
doc_id: 266121
cord_uid: 0tk5u50w

The human CC chemokine receptor 5 (CCR5) is a G protein-coupled receptor (GPCR) that plays a major role in inflammation and is involved in the pathology of cancer, HIV, and COVID-19. Despite its significance as a drug target, the activation mechanism of CCR5, i.e. how chemokine agonists transduce the activation signal through the receptor, is yet unknown. Here, we report the cryo-EM structure of wild-type CCR5 in an active conformation bound to the chemokine super-agonist [6P4]CCL5 and the heterotrimeric Gi protein. The structure provides the rationale for the sequence-activity relation of agonist and antagonist chemokines. The N-terminus of agonist chemokines pushes onto an aromatic connector that transmits activation to the canonical GPCR microswitch network. This activation mechanism differs significantly from other CC chemokine receptors that bind shorter chemokines in a shallow binding mode and have unique sequence signatures and a specialized activation mechanism. One-sentence summary The structure of CCR5 in complex with the chemokine agonist [6P4]CCL5 and the heterotrimeric Gi protein reveals its activation mechanism

The human CC chemokine receptor 5 (CCR5) is a G protein-coupled receptor (GPCR) that plays a major role in inflammation and is involved in the pathology of cancer, HIV, and COVID- 19 . Despite its significance as a drug target, the activation mechanism of CCR5, i.e. how chemokine agonists transduce the activation signal through the receptor, is yet unknown. Here, we report the cryo-EM structure of wild-type CCR5 in an active conformation bound to the chemokine super-agonist [6P4]CCL5 and the heterotrimeric Gi protein. The structure provides the rationale for the sequence-activity relation of agonist and antagonist chemokines. The Nterminus of agonist chemokines pushes onto an aromatic connector that transmits activation to the canonical GPCR microswitch network. This activation mechanism differs significantly from other CC chemokine receptors that bind shorter chemokines in a shallow binding mode and have unique sequence signatures and a specialized activation mechanism.

The human CC chemokine receptor 5 (CCR5) is a G protein-coupled receptor (GPCR) that plays a major role in inflammation by recruiting and activating leukocytes (1) . CCR5 is also the principal HIV coreceptor (2) , is involved in the pathology of both cancer(3) and neuroinflammation (4) , and has been implicated in the inflammatory complications of COVID-19 (5, 6) . Soon after the discovery of CCR5, it became evident that its natural chemokine ligands inhibit HIV entry (7) , with CCL5 (RANTES) being most efficient, both by blocking the binding site for the viral glycoprotein gp120 and by promoting CCR5 endocytosis (8) . Modifications of the N-terminal region of CCR5 preceding C10 yielded HIV entry inhibitors with significantly higher potency (9) (10) (11) . These analogs belong to a group of over 100 engineered CCL5 Nterminal variants that show striking differences in their anti-HIV, endocytotic, affinity, and signaling properties ranging e.g. from super-agonist to strong antagonist behavior (10, 11) . The molecular explanation for these N-terminal structure-related differences is currently unclear.

Whereas a good structural understanding has been reached of the activation mechanisms of class A GPCRs by small-molecule ligands (12) , the activation mechanism of the chemokine receptor subclass is not yet well understood. Inactive structures of a number of chemokine receptors have been solved including complexes of CCR5 with the engineered chemokine antagonist [5P7]CCL5 (13) , the viral gp120•human CD4 complex (14) , the HIV inhibitor maraviroc (15) , and other small-molecule antagonists (16) . In contrast, currently only three active-state chemokine receptor complex structures are available: CX3CL1•US28•Nb7 (17) , CCL20•CCR6•Go (18) , and CXCL8•CXCR2•Gi (19) . The viral receptor US28 is constitutively active and hence does not reveal chemokine-induced activation, and the chemokines CCL20 and CXCL8 adopt a shallow binding mode in which activation apparently involves transmission of forces directly from the extracellular domain of the receptor. On the other hand, receptors such as CCR5 have ligands with longer N-termini which likely insert more deeply into the orthosteric pocket of the receptor (chemokine recognition site 2; CRS2). At least in the case of CCR5, where agonist and antagonist N-terminal CCL5 variants of the same length exist, crucial signaling interactions must rather be located within CRS2.

With the aim of elucidating the apparently different activation mechanisms of CC chemokine receptors and to provide a general structural explanation for the variable pharmacology of CCL5 N-terminal variants, we solved the structure of wild-type human CCR5 in complex with the super-agonist [6P4]CCL5 and the Gi heterotrimer. Fig. S1 ). The complex was treated with apyrase to hydrolyze GDP and was further stabilized by addition of the Fab fragment Fab16 (20, 21) , which recognizes an interface between the Gα and Gβγ subunits of the Gi heterotrimer ( Supplementary Fig. S2 ). Single-particle cryo-electron microscopy (cryo-EM) analysis with extensive particle classification yielded a three- Table S1 ). The map is well resolved for most of parts of CCR5, the [6P4]CCL5 N-terminus, the Gi heterotrimer, and Fab16 ( Supplementary Fig. S4 ). The density of the globular core of [6P4]CCL5 and the adjacent CCR5 N-terminus and extracellular parts of the receptor have less-defined density, indicating relative flexibility in these parts of the structure. Indeed, a 3D variability analysis of the cryo-EM data (Supplementary Video S1) and molecular dynamics simulations of the atomic model ( Supplementary Fig. S5A) Fig. 1C, 2A) . Nevertheless, this minor change in orientation also leads to small (1-2 Å), but noticeable movements at the extracellular helix ends (Fig. 2B) .

The open conformation of the intracellular part of the active CCR5 differs from all inactive CCR5 structures thereby enabling the binding of the G protein (Fig. 1C): TM6 is moved   outwards from the heptahelical bundle accompanied by further rearrangements of TM5, TM7, and intracellular loop 4 (ICL4). The moderate outward displacement of TM6 and the arrangement of Gi relative to CCR5 (Fig. 1A -C) agrees with previous GPCR•Gi complexes (21, 22) .

The interactions between [6P4]CCL5 and CCR5 can be separated into the three canonical chemokine recognition sites (CRS) 1, 1.5, and 2 (13, 23) . CRS1 consists of the contacts of the chemokine core with the extracellular side of the receptor and is dominated by electrostatic interactions. The core of [6P4]CCL5 sits on top of a wide opening in the extracellular part of the CCR5 transmembrane bundle, which is shaped by two disulfide bridges (C101 3.25 -C178 ECL2 , conserved in Class A GPCRs, and C20 N-term -C269 7.25 , specific of chemokine receptors; superscripts indicate the GPCRdb numbering scheme(24)) ( Fig. 1C) . The [6P4]CCL5 strand β1 makes extensive contacts with polar residues in ECL2, while the CCR5 N-terminus directs towards a shallow grove between the chemokine N-loop and 40s-loop forming further extensive ionic and polar interactions. Due to missing density, the model of the CCR5 N-terminus could only be built starting from residue A16. Clear interactions are visible between CCR5 residues S17 and E18 and the chemokine residues R47 and Q48. To gain insights into the missing Nterminal region, CCR5 residues 1-15 were modelled (Fig. 1D ) based on NMR NOE contacts (25) between wild-type CCL5 and an N-terminal fragment of CCR5 sulfated at residues Y10 and Y14. These post-translational modifications are important for chemokine affinity (25) (26) (27) (28) and are expected to be present also in insect cell-expressed CCR5 (29) . The NMR structure of the CCR5-peptide•CCL5 complex (25) is completely compatible with the cryo-EM structure. The in agreement with the NMR observations (28) . In addition, a comparison of MD trajectories between non-sulfated and sulfated CCR5 indicates that sulfation induces a higher number of atomic contacts between the chemokine and the receptor N-terminus ( Supplementary Fig. S5B ), consistent with the higher affinity of the sulfated form (27) .

The N-terminus of [6P4]CCL5 reaches deep into the orthosteric pocket (CRS2) between the CCR5 7TM bundle. This contrasts with the shallow binding modes observed for the chemokines in the CCL20•CCR6•Go (18) and CXCL8•CXCR2•Gi (19) complexes (see below). Of note, the N-terminal residues preceding C10 and C11 of monomeric CCL5 in solution have high nanosecond flexibility (30) . However, they adopt a fixed conformation in the CCR5 complex. Table S2 ), CCR5 internalization, and anti-HIV activity (11) . A sequence analysis shows that residues 0-3 (highest abundance: QGPL) and 8, 9 (highest abundance: QV) are highly similar between 83 low-and 34 high-Ca-signaling N-terminal variants (Fig. 2E ). The latter is not surprising since the selection libraries were to some extent biased towards these residues (11) . In contrast, strong differences are observed for residues 4-7: for agonist variants the small, hydrophilic or negatively charged amino acids S, Q, G, D dominate, whereas antagonist variants contain mostly the large hydrophobic amino acids L, M, W, L. Apparently, the small hydrophilic residues direct the hinge towards K26 1.28 in TM1, whereas the large hydrophobic residues make the hinge collapse to a helical turn. In agreement with their agonist pharmacology, both [6P4]CCL5 and wild-type CCL5 as well as the other major CCR5 agonist chemokines CCL3 (MIP1α) and CCL4 (MIP1β) contain an aspartic acid at positions 5 or 6 ( Fig. 2E) , which strengthens the extended hinge by forming a salt bridge to K26 1.28 . Fig. S8 ) that bring the intracellular half of this helix towards the receptor core. This movement allows H289 7.45 to push on W248 6.48 , possibly assisting the relocation of TM6 (Fig. 3A ). P3 also lays on top of an 'aromatic connector' formed by CCR5 residues Y108 3.32 , F109 3.33 , F112 3.36 , and Y251 6.51 (Fig. 3B) , forcing the movement of Y108 3.32 and resulting in a cascade of aromatic side chain relocations that transmit the activation signal to the receptor core. This allows the switch of the PIF motif (P206 5.50 , I116 3.40 , and Y244 6.44 ) to an active conformation (Fig. 3D ) and the large-scale movement of TM6. The relocation of TM6 and TM7 coincides with local structural changes in the NPxxY motif ( Fig. 3C ) leading to the formation of the conserved water-mediated interaction between Y297 7.53 and Y214 5.58, (31) 

The binding interface of Gi to CCR5 is mediated exclusively by the Gα subunit These interfaces are common to all GPCR/G protein complexes, as they arise from the common overall relative orientation of the bound components. However, analysis of the currently available complexes reveals that the precise location and nature of the individual interface contacts vary to a certain degree ( Supplementary Fig. S12 ). At the proximal rim of the interface, contacts are mostly hydrophobic and consistent with other Gi complexes. At the distal rim, we observe several ionic interactions absent in other structures. However, the most noticeable differences lie in the core region of the binding interface, where we observe different contacts between the hook of α5 (the last three C-terminal residues of Gi) and ICL4 of CCR5.

Interestingly, this is due to a distinct conformation of ICL4 of CCR5 in which G301 8.47 and E302 8.48 slightly relocate compared to other GPCR/Gi complexes, resulting in a different set of interactions between E302 8.48 and the hook of α5 (Fig. 4B) . The varying conformation of the short ICL4 illustrates the structural plasticity of this domain among Gi-binding GPCRs (Supplementary Fig. S13 and S14).

The comparison between our structure and the inactive [5P7]CCL5•CCR5 complex (13) allows us to precisely pinpoint the activation mechanism of CCR5 by a chemokine agonist ( (Fig. 5A ). In the related chemokines CCL3 and CCL4, the aspartates at position 5 and the bulky residues at position 2 can carry out analogous functions.

The activation mechanism in CCL5/CCR5, in which the N-terminus of the chemokine reaches deep into the transmembrane bundle, differs substantially from that of CCL20/CCR6, where a much shorter CCL20 adopts a shallower binding pose and engages a non-canonical activation mechanism(18) (Fig. 2D, 5B) . Thus, CC chemokine receptors can apparently be activated through two very different mechanisms by 'long' and 'short' chemokines. But what are the molecular features in the receptor that determine the type of activation? A phylogenetic analysis of CCR chemokine receptors ( Supplementary Fig. S16 ) puts CCR5 and CCR6 into distinct distant subgroups. A more detailed sequence comparison of key residues in the activation mechanism shows that CCR chemokine receptors can be divided into two main groups according to the nature of the residue at position 6.48 (W vs Q) and, to some extent, of the aromatic connector (Fig. 5C) . Remarkably, CC chemokine receptors featuring the conserved W 6.48 (CCR1, CCR2, CCR3, CCR4, CCR5, and CCR8) tend to be more promiscuous and preferentially recognize chemokines with longer N-termini (9-14 residues) (Fig. 5C ). On the other hand, CC chemokine receptors featuring Q 6.48 (CCR6, CCR9, CCR7, and CCR10) bind to only a few (1-2) chemokines with short N-termini (4-9 residues). Interestingly, although position 6.48 allows for a certain degree of variability in human Class A GPCRs (70% W; 15% F; 5% Y; 10% other), a Q at this position is exclusive of this subgroup of chemokine human receptors, supporting the uniqueness of this 'shallow' activation mechanism.

The structure of CCR5 in an active conformation allows us to elucidate a novel activation pathway of CC chemokine receptors by a chemokine agonist. In CCR5 and related receptors (CCR1, CCR2, CCR3, and CCR4), the respective cognate chemokines have long N-termini and bind deep into the orthosteric pocket (CRS2) thereby triggering the rearrangement of an aromatic connector in TM3 and TM6 and of the TM7 backbone. W 6.48 lies at the center of these conformational changes connecting the receptor activation pathways through TM7 and TM6. In contrast, a subgroup of CC chemokine receptors (CCR6, CCR7, CCR9, and CCR10) harbor a Q residue at this position, a unique feature in human Class A GPCRs. The cognate chemokines of these receptors have shorter N-termini featuring a shallow binding mode and a specialized mode of activation. We expect that our findings will help to rationalize the relationship between sequence, structure, and activity of chemokines and their receptors and aid drug discovery.

The wild-type human CCR5 gene containing a C-terminal 3C cleavage site followed by a FLAG-tag was cloned into the pFastBac1 vector and expressed in Spodoptera frugiperda Sf9 insect cells using the baculoviral infection system. CCR5 expression and membrane preparation were performed as described (15) . Membranes from 1-L culture of Sf9 cells were resuspended in 10 ml lysis buffer containing 2 mg/ml iodoacetamide, and EDTA-free complete protease inhibitor cocktail tablets, and incubated at 4°C for 1 hour. Then membranes were solubilized by The human Gαi subunit (Gαi1) with an N-terminal TEV protease-cleavable deca-histidine tag was expressed in the E. coli BL21 (DE3) strain and purified as described (21) .

The transducin heterotrimer was isolated from the rod outer segment of bovine retina (W L Lawson Company) and Gβ1γ1 was separated from Gαt with Blue Sepharose 6 Fast Flow (GE Healthcare) as described (21) . The Gαi1β1γ1 heterotrimer (Gi) was prepared by mixing equimolar amounts of Gαi1 and Gβ1γ1 and incubated at 4°C for 1 h shortly before use for CCR5-Gi complex formation.

Fab16 was produced by papain digestion of IgG16 as described (21) . Fig. S1A,B) . Fractions showing good purity and complex integrity were pooled together and concentrated for EM grid preparation. 

Contaminated micrographs were removed manually. Patch motion correction and Patch CTF parameter estimation were performed using algorithms implemented in CryoSparc v2.15.0(36).

After sorting, micrographs with estimated resolution worse than 6.0 Å were discarded. The Reported resolutions calculated with a soft shape mask are based on the gold-standard Fourier Shell Correlation (FSC) using the 0.143 criterion. The local resolution was determined using ResMap (37) .

The crystal structures of the Gi heterotrimer (PDB ID: 5KDO), Fab16 (PDB ID: 6QNK and the [5P7]CCL5•CCR5 complex (PDB ID: 5UIW) were used as initial templates for model building. The models were docked into the 3D map as rigid bodies in Chimera (38) . The Supplementary Table S1 .

The analysis of N-terminal sequence similarity of the natural amino acid CCL5 variants (Supplementary Table S2 ) was carried using WebLogo (41) .

The purified [6P4]CCL5•CCR5•Gi complex with or without Fab16 was incubated with 100 µM GTPγS in 25 mM HEPES, 150 mM NaCl, 0.01% LMNG, pH 7.5 for 1 h at 4 °C followed by SEC analysis on a Superdex 200 Increase 10/300 monitoring the protein intrinsic tryptophan fluorescence with the excitation wavelength at 280 nm and emission wavelength 350 nm (Supplementary Fig. S1C ). (C10-C34 and C11-50) were explicitly defined during model building. All models were subjected to 300 iterations of variable target function method optimization and thorough molecular dynamics and simulated annealing optimization and scored using the discrete optimized protein energy potential. The 20 best-scoring models were analyzed visually, and a suitable model (in terms of low score and overall structure) was selected ( Figure 1D , right panel).

This model of CCR5 (residues 1-320) bound to [6P4]CCL5 was used for molecular dynamics simulations of the non-sulfated and sulfated (Y10 and Y14) forms. Coordinates were first pre-processed using VMD1.9.3 (43) . The receptor-ligand complex (i.e. CCR5-[6P4]CCL5 or CCR5-CCL5) was then embedded into a 90 Å x 90 Å lipid bilayer composed of 80% 1palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 20% cholesterol. The system was solvated with explicit water molecules, neutralized, and its ionic strength was adjusted using the CHARMM-GUI builder (44) . Disulfide bridges were explicitly defined between: C50-C11 and C34-C10 in CCL5 or [6P4]CCR5, and C101 3.25 -C178, and C20-C269 7.25 in CCR5. Except for CCR5 residues D76 2.50 , E283 7.39 , and E302 8.48 , which were protonated, all titratable residues of CCR5 and CCL5 were left in their dominant protonation state at pH 7.0. Prior to production runs, the geometry of the system was optimized by energy minimization and further relaxed by a sequence of equilibration steps where harmonic positional restraints were applied to all Cα atoms of the protein, and gradually released throughout the equilibration. In the last equilibration step (i.e. before completely releasing all protein restraints), water, ion and lipids were allowed to diffuse without restraints during 50 ns to allow for adequate equilibration of the lipid mixture.

Upon equilibration was completed, five independent trajectories of each system were spawned from the last snapshot of the equilibrated trajectory using a random seed. Production simulations for each replica were run in the NPT ensemble at 1,013 bar and 310 K for 500 ns each. All simulations were run using Gromacs v2020 (45) with the CHARMM36m force field (46) . Gromacs v2020 and VMD1.9.31, were used to post process and analyze all trajectories. MD simulation figures were rendered using VMD1.9.3, and the R ggplot2 library (47) . QGPPGDIVLACC / CCL5: SPYSSDTTP-CC) and steric clashes were relieved using the molecular graphics software PyMOL. Using this structure as a template, residues 1-9 of CCL5 and all residues 8 Ångstrom around Y3 of CCL5 were re-modeled with Modeller v9.16 using the protocol described above. The stability of the resulting binding pose was assessed by molecular dynamics simulations using the protocol described above.

A list of simulations performed in this work is given in Supplementary Table S3 

G.F.X.S. declares that he is a co-founder and scientific advisor of the companies leadXpro AG and InterAx Biotech AG.

Table S1 -S3 TM5  TM4   TM3   TM3   TM1   TM7   TM7 

CCR5: Established paradigms and new frontiers for a 'celebrity' chemokine receptor

The biology of CCR5 and CXCR4. Current opinion in HIV and AIDS

Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer

CCR5 blockade for neuroinflammatory diseases -beyond control of HIV

COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis

Identification of rantes, mip-1-alpha, and mip-1-beta as the major hiv-suppressive factors produced by Cd8(+) tcells

Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines

Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist

Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors

Highly potent, fully recombinant anti-HIV chemokines: Reengineering a low-cost microbicide

The Molecular Basis of G Protein-Coupled Receptor Activation

Structure of CC chemokine receptor 5 with a potent chemokine antagonist reveals mechanisms of chemokine recognition and molecular mimicry by HIV

Structural basis of coreceptor recognition by HIV-1 envelope spike

Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex

Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists

Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor

Structural basis for chemokine receptor CCR6 activation by the endogenous protein ligand CCL20

Structural basis of CXC chemokine receptor 2 activation and signalling

Development of an antibody fragment that stabilizes GPCR/G-protein complexes

Cryo-EM structure of the rhodopsin-Gαi-βγ complex reveals binding of the rhodopsin C-terminal tail to the gβ subunit. eLife

Crystal structure of the b2 adrenergic receptor-Gs protein complex

Pharmacological modulation of chemokine receptor function

Generic GPCR residue numbersaligning topology maps while minding the gaps

The solution structure of monomeric CCL5 in complex with a doubly sulfated N-terminal segment of CCR5

Tyrosine Sulfation of the Amino Terminus of CCR5 Facilitates HIV-1 Entry

Recognition of RANTES by extracellular parts of the CCR5 receptor

Allovalency observed by transferred-NOE: Interactions of sulfated tyrosine residues in the N-terminal segment of CCR5 with the CCL5 chemokine

Large-scale expression and purification of the major HIV-1 coreceptor CCR5 and characterization of its interaction with RANTES. Protein expression and purification

Characterization of structure, dynamics, and detergent interactions of the anti-hiv chemokine variant 5P12-RANTES

A high-resolution description of β 1 -adrenergic receptor functional dynamics and allosteric coupling from backbone NMR

Activation of CCR5 by Chemokines Involves an Aromatic Cluster between Transmembrane Helices 2 and 3

Automated electron microscope tomography using robust prediction of specimen movements

Software tools for automated transmission electron microscopy

Focus: The interface between data collection and data processing in cryo-EM

cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

Quantifying the local resolution of cryo-EM density maps

UCSF Chimera-A visualization system for exploratory research and analysis

Features and development of Coot

Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix

WebLogo: A sequence logo generator

VMD: Visual molecular dynamics

Automated Builder and Database of Protein/Membrane Complexes for Molecular Dynamics Simulations

GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers

CHARMM36m: an improved force field for folded and intrinsically disordered proteins

Ggplot2: elegant graphics for data analysis

Electrostatics of nanosystems: Application to microtubules and the ribosome

International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors

UniProt: a worldwide hub of protein knowledge

Detailed view of [6P4]CCL5 N-terminus inserted into active CCR5, [5P7]CCL5 N-terminus, and gp120 V3-loop inserted into inactive CCR5; and comparison of the insertion of [6P4]CCL5 N-terminus into active CCR5 and of CCL20 N-terminus into active CCR6 (PDB ID: 6WWZ). (E) Sequence composition of the Ntermini of CCL5 natural amino acid variants (Supplementary Table S2) with low (≤20%, N=83, top) and high (≥50%, N=34, bottom) Ca-signaling. The N-termini of